Similar articles

• [Coordinated platinum compounds in experimental and clinical oncology].

  Lobanova EA, Kozlova MD, Singin AS, Serebriakov NG. Lobanova EA, et al. Med Radiol (Mosk). 1984 Jun;29(6):59-63. Med Radiol (Mosk). 1984. PMID: 6376996 Review. Russian. No abstract available.
• [Antitumor effect of complex compounds of tetravalent platinum].

  Konovalova AL, Presnov MA, Zheligovskaia NN, Treshchalina EM. Konovalova AL, et al. Dokl Akad Nauk SSSR. 1977 May-Jun;234(1):223-6. Dokl Akad Nauk SSSR. 1977. PMID: 880861 Russian. No abstract available.
• Low in vivo toxicity of a novel cisplatin-ursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors.

  Dominguez MF, Macias RI, Izco-Basurko I, de La Fuente A, Pascual MJ, Criado JM, Monte MJ, Yajeya J, Marin JJ. Dominguez MF, et al. J Pharmacol Exp Ther. 2001 Jun;297(3):1106-12. J Pharmacol Exp Ther. 2001. PMID: 11356935
• [Animal experimental examination of a phase III study on the effect of the combination therapy of bruneomycin, cytostasan and prednisone].

  Nowak C, Arnold W, Henneberger G, Tanneberger S. Nowak C, et al. Arch Geschwulstforsch. 1983;53(1):37-44. Arch Geschwulstforsch. 1983. PMID: 6344835 Clinical Trial. German.
• Organo-platinum complexes as antitumor agents (review).

  Hill JM, Speer RJ. Hill JM, et al. Anticancer Res. 1982 May-Jun;2(3):173-86. Anticancer Res. 1982. PMID: 6751211 Review.